An interventional study of TWIICE Rise 1.0 robotic exoskeleton combined with epidural electrical stimulation (EES) in Spinal Cord Injury, sponsored by Ecole Polytechnique Fédérale de Lausanne. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Ecole Polytechnique Fédérale de Lausanne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Spinal Cord Injuries with a site in Switzerland — 25 open to participants now, 31 under way, none of them phase 3. Spinal Cord Injuries · Switzerland.
Among the 111 studies in Spinal Cord Injuries with a site in Switzerland, this one is the 52nd largest by planned enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2026, is one of 59 with no phase, reaches primary completion later than 18 of the 30 other live ones, and was the 108th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →25 of the 111 studies in Spinal Cord Injuries with a site in Switzerland are open now. Recruiting first, the newest first:
NovaGo Therapeutics AG · Sites in Switzerland, Germany
Ages 18–75
Swiss Paraplegic Research, Nottwil · Sites in Switzerland
Ages 18–70
Swiss Paraplegic Research, Nottwil · Sites in Switzerland
Ages 18+
Ecole Polytechnique Fédérale de Lausanne · Sites in Switzerland
Ages 18–65
Swiss Paraplegic Research, Nottwil · Sites in Switzerland
Ages 18–75
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 1 · Phase 4 2
First in 2004; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 21 across the 72 interventional studies, 50 across the 39 observational. Of the 72 that completed or were terminated, 4 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 111 have an industry lead sponsor. The 10 most frequent:
Ecole Polytechnique Fédérale de Lausanne is the lead sponsor of 21 studies on the registry; 11 are open to participants now.
Ecole Polytechnique Fédérale de Lausanne has 8 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
10 of the studies in Spinal Cord Injuries with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01571531University of ZurichEuropean Multicentre Study of Human Spinal Cord Injury | 2026-12 |
| NCT03053791University of ZurichDeep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait | 2026-12 |
| NCT07739134ETH ZurichMultimodal Tracking of Therapy Activity and Effort During Rehabilitation | 2026-12-30 |
| NCT06845904Ecole Polytechnique Fédérale de LausanneStudy on Preliminary Safety and Efficacy of Epidural Electrical Stimulation to Manage Lower Urinary Tract Dysfunction After Spinal Cord Injury | 2027-02 |
| NCT06817577NovaGo Therapeutics AGNG004 in Spinal Cord Injury Patients | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 111 studies in Spinal Cord Injuries with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate the preliminary safety and feasibility of using the VALSE system, which combines spinal cord stimulation with the TWIICE robotic exoskeleton, to support motor recovery and reduce reliance on laboratory-based equipment during rehabilitation in participants with traumatic spinal cord injury. The TWIICE exoskeleton is integrated through the NR system, a platform developed by EPFL. The goal is to assess the clinical safety and practical application of this combined neuroprosthetic approach in a small number of participants, in order to guide future refinements of the device and protocol, support the development of scalable interventions integrating spinal stimulation with robotic assistance, and inform strategies for delivering rehabilitation in more accessible, real-world environments.
Spinal cord injury (SCI) disrupts communication between the brain and spinal cord below the lesion, often resulting in severe and permanent motor impairments. Despite advances in rehabilitation, recovery of walking remains limited and restoring mobility is consistently identified as a top priority by individuals living with SCI.
Epidural electrical stimulation (EES) of the spinal cord has emerged as a promising approach to restore movement after paralysis. By activating spinal motor circuits below the lesion, EES can enable standing, stepping, and walking in individuals with chronic SCI. ONWARD Medical has developed the ARC-IM spinal stimulation platform, which is currently being evaluated in several clinical studies, including BoxSwitch (NCT05942339), Think2Go (NCT06243952), and STIMO-BSI (NCT04632290).
In the BoxSwitch trial, optimized spatiotemporal EES protocols enabled participants with chronic SCI to perform standing, stepping, and walking movements. Building on these findings, the Think2Go and STIMO-BSI studies integrated the WIMAGINE implantable electrocorticography (ECoG) system developed by Clinatec (CEA, Grenoble, France) with spinal stimulation, creating a brain-spine interface capable of decoding motor intentions and translating them into spinal stimulation. These studies demonstrated that implantable brain-spine interfaces can restore voluntary control of lower-limb movements and support functional walking after severe paralysis.
Although these technologies have shown encouraging results, their use remains largely restricted to specialized rehabilitation settings. In parallel, robotic exoskeletons have been developed to support overground walking in individuals with SCI. The TWIICE exoskeleton is a lightweight and modular system specifically designed for use beyond rehabilitation centers and may complement spinal stimulation by providing functional support during walking.
In this study, the investigators will evaluate the preliminary safety and feasibility of the VALSE system, which combines the ARC-IM spinal cord stimulation platform with the TWIICE robotic exoskeleton in individuals with chronic traumatic SCI. Participants will be recruited from ongoing clinical studies at Lausanne University Hospital (CHUV), including BoxSwitch (NCT05942339), Think2Go (NCT06243952), and STIMO-BSI (NCT04632290), after completion of the relevant study phases.
As an early feasibility investigation, the study aims to generate preliminary safety and usability data on the combined use of spinal neuromodulation and robotic assistance during mobility tasks. The results will support the development of future neuroprosthetic solutions designed to improve walking ability, independence, and quality of life for people living with SCI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dual Energy X-ray Absorptiometry (DEXA) results indicating a t-score below -3.5 at either the femoral neck or the total proximal femur.
Dual Energy X-ray Absorptiometry (DEXA) results indicating a bone mineral density (BMD) \< 0.60 gm/cm2 at any knee region (distal femur, proximal tibia)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive the same intervention. Each participant will complete 3 predefined study periods within 1 year of enrolment. Each study period lasts 3 weeks, and study periods are separated by a minimum interval of 1 month.
Combination Product: TWIICE Rise 1.0 robotic exoskeleton combined with epidural electrical stimulation (EES)
Participants will use the VALSE system, which combines the TWIICE Rise 1.0 robotic exoskeleton with epidural electrical stimulation (EES) delivered through previously implanted neuromodulation systems. The system is intended to support upright mobility and overground walking in individuals with chronic spinal cord injury (SCI) who are currently enrolled in, or have completed key phases of, neuromodulation clinical trials at CHUV, including Think2Go (NCT06243952), STIMO-BSI (NCT04632290), and BoxSwitch (NCT05942339). The TWIICE exoskeleton provides robotic gait assistance, while EES facilitates activation of spinal motor circuits below the level of injury. Exoskeleton movements are initiated and controlled through participant-generated inputs, including finger-click commands and, where applicable, brain-derived control signals from previously implanted brain-spine interface systems. The VALSE system is used in supervised clinical and controlled real-world.
Preliminary safety
Occurrence of Serious Adverse Events (SAE) and Adverse Events (AE) that are deemed related or possibly related to the procedure or to the TWIICE exoskeleton in combination with the neuromodulation therapies (VALSE system)
Time frame: From enrollment until the end of study timepoint, up to 1 year after enrollment.
Assessment of the experimental session conditions
Location and type of ground walked on.
Time frame: At each in-clinic training session during the three study periods, up to 1 year after enrollment.
Number of steps
Total number of steps recorded by the exoskeleton during each experimental (EX) session.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Step frequency
Average step frequency (cadence) recorded by the exoskeleton during each experimental (EX) session.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Mid-stride pauses
Number of mid-stride pauses recorded by the exoskeleton during each experimental (EX) session.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Distance walked
Total distance walked recorded by the exoskeleton during each experimental (EX) session.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Walking time
Total walking time recorded by the exoskeleton during each experimental (EX) session.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Standing time
Total standing time recorded by the exoskeleton during each experimental (EX) session.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Kinematic gait parameters
Kinematic gait parameters recorded during overground walking and functional locomotor tasks (change of walking speed, stepping over and turn around obstacles, climb stairs, walk with cognitive load (e.g., counting backward by threes)) using the VALSE system.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Electromyographic (EMG) activity
Muscle activation patterns recorded by surface electromyography during overground walking and functional locomotor tasks while using the VALSE system.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Brain-computer interface (BCI) performance
Brain-computer interface performance metrics recorded during overground walking and functional locomotor tasks while using the VALSE system.
Time frame: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
Donning and Doffing Time
Assessment of the time it takes to put on and take off the system. Donning time is recorded from the start of preparation until the participant is fully ready for ambulation. Doffing time is recorded from the start of removal until the participant is fully disengaged from the system.
Time frame: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
Level of Assistance (LOA)
Assessment to evaluates the amount of physical support required by the participant during walking and mobility activities with the device.
Time frame: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
System Usability Scale (SUS)
A validated 10-item questionnaire measuring usability across multiple domains. Scores range from 0-100, with higher values indicating greater usability. Will be filled in by participants and physiotherapists.
Time frame: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
ASA Task Load Index (NASA-TLX)
A 6-dimension tool assessing perceived workload (mental demand, physical demand, temporal demand, performance, effort, frustration). Will be filled in by participants and physiotherapists.
Time frame: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
Plan to share: No
Start is estimated for Sep 2026; primary completion for May 2028, 20 months later.
Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 20 months is below that.
Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ecole Polytechnique Fédérale de Lausanne